Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

ition patients to open-label anticoagulation at the end of the trial, which resulted in a low and evenly distributed number of events post-discontinuation of study therapy. In the 30 days following the transition, the number of patients experiencing stroke or SEE was the same in all three treatment groups (n=7), while major bleeding occurred in 11 patients in the warfarin group compared to 10 and 18 patients in the edoxaban 60 mg and 30 mg treatment arms, respectively. These results demonstrate that the transition plan was effective in preventing undue risk of excessive stroke / SEE for edoxaban-treated subjects transitioning to a vitamin K antagonist (VKA) or a novel oral anticoagulant.2

About Atrial Fibrillation

Atrial fibrillation (AF) is a condition in which the heartbeat is rapid and irregular, and can potentially lead to a stroke. AF is a common condition, affecting approximately 1-2% of people in developed nations.3 Stroke is the second most common cause of death worldwide, responsible for approximately 6.2 million deaths each year.4 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.3 Strokes due to AF are nearly twice as likely to be fatal than strokes in patients without AF5 and have poorer prognosis than non-AF related strokes with a 50% increased risk of remaining disabled at three months.6

About Edoxaban

Edoxaban is an investigational, oral, once-daily anticoagulant that specifically and reversibly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.7 The global edoxaban clinical trial program includes two phase 3 clinical trials, Hokusai-VTE8 and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation)1,2, which are evaluating edoxaban, administered once-daily, for tre
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 /CNW/ - Atlantic Canadians will save ... between Canada,s provinces and territories ... President of the Canadian Generic Pharmaceutical Association (CGPA), said ... while speaking at the Atlantic Summit on Healthcare and ... which is being hosted by the Public Policy Forum ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it ... Administration ("FDA") of the successful completion of an inspection ... first product to market.  Under the Company,s Consent Decree, ... and facilities are expected to be required before K-V ...
... Inc. Promote PurCotton(R) Brand in Shenzhen -- SHENZHEN, China, Sept. 10 /PRNewswire-Asia/ -- ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 2Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 3Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 4Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 5Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 6Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 7Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 8
(Date:10/31/2014)... In the first study of its kind, Rice University ... circuits that cause cancer cells to become metastatic. The ... allows cancer cells to both migrate and form new ... to new drugs that interfere with the genetic switches ... cells and circulating tumor cells -- two of the ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss ... fastest fat loss program ever developed. It promises to provide ... There is no wonder after all that this has become ... new nutrition and workout fat loss program was created by ... According to the author of this fat loss system, the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 With all ... one Midwest optometrist feels they may overlook one critical ... affect areas like concentration, school performance and even behavior. ... too brief to identify progressive vision problems, and to ... Mo., announces a new initiative: The Awesome Eyes Student ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Sleep apnea may make it hard ... parked your car or left your house keys, a small ... apnea showed that this ability -- called spatial memory -- ... sleep, even when other stages of sleep weren,t affected. REM ... typically occur. "We,ve shown for the first time that ...
(Date:10/31/2014)... of four older Americans say that either they or ... treatment, according to the latest issue of The Gerontological ... ( PP&AR ), which goes on to show ... fail to honor patients, end-of-life health care wishes. , ... Issues and Options ," features 12 articles that present ...
Breaking Medicine News(10 mins):Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... ... Better , ... 2010 -- He,s no guru. And he’s not selling a philosophy, a religion, or telling ... Still the stories surrounding this young Croatian have spawned hundreds of thousands all over Europe ...
... it helps build strength and flexibility, aids relaxation, experts ... is safe for pregnant women, as long as they ... say. , "Women who are expecting can benefit greatly ... be aware of their limitations," orthopaedic surgeon and mom-to-be ...
... ... nasty germs has just become a little easier. If you’re like most of ... spraying everything is sight. Let’s face it -- no one likes germs. ... Arnot Thursday, May 27th at 7:00am (ET/PT), as they air on Lifetime Television. ...
... Highly anticipated Speed ... ... Trek Bicycle , the world leader in bicycle technology and innovation, officially launched its ... the backdrop of the Amgen Tour of California’s Stage 7 Time Trial in Los Angeles. ...
... ... software to Windows dedicated server & Windows VPS (virtual private server) hosting clients at ... customer service software and SmarterStats Web log analytics and SEO software. It is valued ... ...
... ... ... On this edition of The Balancing Act, we are bringing viewers some vitally important information about ... talk about a plan that can help make sure that your family is covered. , ...
Cached Medicine News:Health News:Regular Guy "Braco" Healing Masses in Europe 2Health News:Yoga's Benefits Outweigh Risks for Pregnant Women 2Health News:O2 Media's Hit Morning Show ‘The Balancing Act' Welcomes Dr. Bob Arnot to the Program 2Health News:Trek Introduces Speed Concept Triathlon Bikes 2Health News:Trek Introduces Speed Concept Triathlon Bikes 3Health News:Trek Introduces Speed Concept Triathlon Bikes 4Health News:Dedicate Server and VPS Hosting Provider Company HostRightNow Technologies Partners with SmarterTools Inc. 2Health News:O2 Media's Hit Morning Show ‘The Balancing Act' Welcomes HSA Bank to the Program 2
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and semi-qualitative detection of antinuclear antibodies to aid in the diagnosis of systemic lupus erthyematosus....
... Rapid Plasma Reagin card ... detection and quantitative determination ... or plasma. Uses carbon ... detect reagin. Kits include ...
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: